Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis.

A 1‐way repeated measures ANOVA analysis with K i in NAWM pretreatment and 6 months posttreatment as outcome and baseline methylprednisolone, days since last relapse, and first‐line treatment as covariates found no significant effect of time ( p = 0.079), but the interaction between time and baseline methylprednisolone showed a trend ( p = 0.041; Fig 4 ).

also in 53,322 other papers